NASDAQ: TRDA
Entrada Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$274.07M
52w High
$16.45
52w Low
$4.93
P/E
-1.78
Volume
588.92K
Outstanding Shares
38.82M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 21.1% over the last year. Revenue declined 94.1% over the trailing twelve months. Operating margin moved from -121% to -3,767.07%. Free cash flow declined 6.16% over the trailing twelve months.
What the market seems to be pricing
The stock is rising despite deteriorating fundamentals and now sits at the 86th percentile of its historical P/S range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.
What would invalidate this read
Operating margin (currently -3,767.07%) would need to stabilize or improve to justify the move. Revenue is declining 94.1% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.
Company profile
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est -$1.00 · Revenue est $6.98M
View